Completed PHASE2 INTERVENTIONAL 3-arm NCT00078754

A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder

Fluoxetine and Divalproex: Treatment Correlates in IED

Sponsor: National Institute of Mental Health (NIMH)

Conditions Intermittent Explosive Disorder

Interventions Divalproex Fluoxetine Placebo

Updated 10 times since 2017 Last updated: Apr 26, 2021 Started: May 31, 2003 Primary completion: Oct 31, 2008 Completion: Oct 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Intermittent Explosive Disorder, this trial is completed. The trial is conducted by National Institute of Mental Health (NIMH) and has accumulated 10 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Dec 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

May 2021 — Dec 2021 [monthly]

Completed PHASE2
Jan 2021 — May 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Mental Health (NIMH)
University of Chicago

Data source: University of Chicago

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States